Navigation Links
Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:8/31/2010

ans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property protection, product development, manufacturing plans and performance, projected changes in the size of our markets, our market share and product sales and other statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships; the market acceptance of our products; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation of incurring continued losses; our uncertainty of product revenues and profits; our ability to generate future revenues; our ability to raise additional capital to continue our drug development programs; the success of our clinical trials; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; our compliance with all Food and Drug Administration regulations; our ability to obtain; maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales and manufacturing capabilities; our dependence on third-party manufacturers and value added resellers; our ability to hire and retain skilled personnel; our volatile stock price; and other risks detailed in Repligen's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially fr
'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
6. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
7. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
8. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
9. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... BAUDETTE, Minn. , March 5, 2015 /PRNewswire/ ... ) today announced that it has acquired the ... Acetate tablets USP 50mg, 100mg and 150mg, previously ... the overall market for this product was approximately ... Arthur S. Przybyl , President and CEO of ...
(Date:3/5/2015)... - Cross reference: Picture is available via ... Hitachi Medical Systems Europe è lieta di ... 2015. Si tratta di un sistema di RM ... migliora la capacità diagnostica dei sistemi già esistenti e ... Le nuove funzionalità di OASIS permettono una migliore gestione ...
(Date:3/5/2015)... 05, 2015 Research and Markets ... the "Global Pharma US & EU Outlook ... Major Role In Shaping Up Business for Large ... Strategy Diversification Divested: Productivity measurements, ... position- Will accelerate Next wave of targeted acquisition ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 2Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 3Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 4Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 2Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 3
... FORD, Pa., Jan. 31, 2011 Endo Pharmaceuticals (Nasdaq: ... Co., Ltd. and Teikoku Pharma USA, Inc.,  have received a ... the filing of an Abbreviated New Drug Application (ANDA) for ... The company is currently reviewing the details of ...
... Get content from Bill & Melinda Gates ... Prime Minister David Cameron said today that the ... polio eradication. Mr. Cameron called on other donors ... he announced the UK,s commitment that will see ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 2Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 3Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 4
(Date:3/5/2015)... March 05, 2015 Developers and plugin ... have announced a new transition pack entitled TranSlice Wipe ... split screen transitions with ease while maintaining a professional ... “TranSlice Wipe is a time saver with transitions our ... Studios brings back split screen transitions with a new ...
(Date:3/5/2015)... Viejo, California (PRWEB) March 05, 2015 ... X plugins have announced a new effect preset ... “ProHalftone allows users to take advantage of combining halftone ... the competition,” said Christina Austin, CEO of Pixel Film ... our users will love.” , With ProHalftone users can ...
(Date:3/5/2015)... The pleasing melodies of live bluegrass music will greet ... and hand cycle ride as they arrive in Frederick, Maryland ... Band will present a free concert for riders who ... in Arlington, Virginia. , “We are thrilled and honored to ... sacrificed so much. We love being to give back a ...
(Date:3/5/2015)... 05, 2015 The cornerstone of the ... faster, safer, smarter commercial lifting system and with the ... increasing role in more green construction projects . ... – Octapad System for lifting concrete road slabs and ... road construction projects. , The Octapad System was ...
(Date:3/5/2015)... March 05, 2015 Hoggan ... dynamometers, ergoFET physical therapy, ergonomic force gauges, ... for ergonomics, engineering, and research applications, introduced ... Dynamometer, available at http://www.HogganHealth.net . The ... offer healthcare professionals a handgrip muscle strength ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released TranSlice Wipe Exclusively for Final Cut Pro X Editors 2Health News:Pixel Film Studios Released ProHalftone Exclusively for Final Cut Pro X Editors 2Health News:Flower Hill String Band to Welcome Face of America with Bluegrass Music 2Health News:Flower Hill String Band to Welcome Face of America with Bluegrass Music 3Health News:New Vacuworx Concrete Lifting Systems Aid Safer, Greener Environment As Contractors Seek LEED Incentives 2Health News:New Vacuworx Concrete Lifting Systems Aid Safer, Greener Environment As Contractors Seek LEED Incentives 3Health News:New Handgrip Strength Tester Receives Rave Reviews At Physical Therapy Conference 2
... , LOS ANGELES ... of menopause , there is a new ray of hope in the ... Shoreh Ershadi and the ANTI AGING Institute of California ... signs and symptoms of menopause with ingredients like green tea extract, pomegranate ...
... treatment, USPSTF panel says, , MONDAY, Jan. 18 (HealthDay ... has issued new recommendations encouraging U.S. doctors to screen ... offer them a referral to intensive weight management programs ... Services Task Force (USPSTF) update those issued in 2005. ...
... The ... conditions, including: Alzheimer,s disease, Traumatic Brain Injury, Schizophrenia and more. , ... Mountain View, CA (PRWEB) ... the launch of HAPPYneuron PRO, an online professional destination that delivers managed cognitive therapies ...
... ... ... Janibell announces the all new M400D Diaper Disposal System. This large 15 gallon model ... are dropped into this container, users never see, smell, or touch the contents again. , ...
... , WASHINGTON , Jan. 17 Members of ... response team from London arrived today in Haiti ... others who are suffering from the disaster. They are accompanied by ... who is bringing in mobile medical units. , Though the ...
... has found 13 new genetic variants that influence blood ... beta cells in populations of European descent. Five ... developing type 2 diabetes, the most common form of ... conducted by the Meta-Analyses of Glucose and Insulin Related ...
Cached Medicine News:Health News:100% Natural Remedy for Menopause Symptoms Offers Guaranteed Satisfaction 2Health News:100% Natural Remedy for Menopause Symptoms Offers Guaranteed Satisfaction 3Health News:Federal Panel Urges Obesity Screening for Kids Ages 6 and Up 2Health News:Federal Panel Urges Obesity Screening for Kids Ages 6 and Up 3Health News:HAPPYneuron Launches the First Online Professional Destination for Clinical Cognitive Training. 2Health News:HAPPYneuron Launches the First Online Professional Destination for Clinical Cognitive Training. 3Health News:A Breath of Fresh Air for Child Care Centers 2Health News:HelpAge Staff Mobilizes for Older People Despite Challenges in Haiti 2Health News:Newly identified genes influence insulin and glucose regulation 2Health News:Newly identified genes influence insulin and glucose regulation 3
0.3% Yeast Extract, 0.3% Malt Extract, 0.5% Peptone, and 1.0% Glucose....
Tryptone is the pancreatic digest of casein used as a nitrogen source for bacteria. Ideal for general bacteriological use with a variety of microorganisms. Tryptone is guaranteed BSE-Free....
Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
... units Penicillin/25,000 ug Streptomycin ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
Medicine Products: